Aspen Targets Mounjaro Expansion in Africa Following Approval
Aspen's Mounjaro expansion plans promise to enhance diabetes and weight management treatment in Sub-Saharan Africa soon.
Aspen Boosted by Mounjaro: A New Era in Weight Loss
Aspen shares soar following the approval of Mounjaro for weight loss in South Africa. Discover the impact on obesity management.
Aspen Unlocking Value with New Manufacturing Strategies
Understand Aspen Unlocking Value efforts as CEO Stephen Saad addresses the decline in share price and targets business improvements.
Aspen Shares Nosedive 15% on JSE After Shock Profit Warning
Aspen Pharmacare shares see a sharp decline on the JSE following an alarming profit warning. What does it mean for investors?
Pharma Giants Sidelined in R15.5bn HIV Drug Tender
The recent R15.5 billion ARV tender sidelines Pharma Giants in South Africa, raising questions about local production support.
Ozempic and Mounjaro are reshaping South Africa’s health market
Understand the significance of Ozempic and Mounjaro in the evolving landscape of diabetes care and weight management in South Africa.
Aspen Pharmacare Manufacturing Dispute Shrouded in Mystery
Explore the Aspen Pharmacare manufacturing dispute and its potential impact on core earnings for the 2025 financial year.
FDA warns Aspen Pharmacare over eye drop production standards
The US FDA has warned Aspen Pharmacare, Africa's largest drugmaker, citing breaches in manufacturing standards for eye drops produced at its Gqeberha facility.
Aspen secures licensing agreement to enter GLP-1 market
Aspen Pharmacare has secured a licensing agreement to enter the GLP-1 agonist market, positioning it for growth in diabetes and obesity treatment solutions.